CWP
COLL icon

Concord Wealth Partners’s Collegium Pharmaceutical COLL Stock Holding History

Concord Wealth Partners’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145 Buy
+4
New +$137 ﹤0.01% 856
2026
Q1 		– Sell
-4
Closed -$185 – 307
2025
Q4 		$185 Hold
4
– – ﹤0.01% 804
2025
Q3 		$140 Hold
4
– – ﹤0.01% 801
2025
Q2 		$118 Buy
+4
New +$114 ﹤0.01% 831

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Concord Wealth Partners's COLL Position: Q2 2026 in Review

Concord Wealth Partners opened a new position in Collegium Pharmaceutical (COLL) in Q2 2026: 4 shares worth $145. The stake represents ﹤0.01% of the portfolio and ranks #856 among its holdings. This is a return to the name: Concord Wealth Partners previously reported a position in COLL as recently as Q4 2025.

Concord Wealth Partners first reported a position in COLL in Q2 2025 and has held it in 4 quarters since. The position peaked at $185 in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Concord Wealth Partners held 4 shares of Collegium Pharmaceutical worth $145 as of Q2 2026.
  • Collegium Pharmaceutical was a new Concord Wealth Partners position in Q2 2026.
  • Collegium Pharmaceutical made up ﹤0.01% of Concord Wealth Partners's portfolio in Q2 2026, its #856 holding.
  • Concord Wealth Partners first reported a position in Collegium Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • Concord Wealth Partners's Collegium Pharmaceutical position peaked at $185 in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Concord Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.